Anzeige
Erschienen in:
01.12.2013 | Original Article
The utility of the IGF-I generation test in children with chronic kidney disease
Erschienen in: Pediatric Nephrology | Ausgabe 12/2013
Einloggen, um Zugang zu erhaltenAbstract
Background
To determine if the insulin-like-growth factor (IGF-I) generation test is a marker for growth hormone (GH) sensitivity in children with chronic kidney disease (CKD).
Methods
This was a randomized cross-over study in which children with CKD received low-dose (0.025 mg/kg/day) and high-dose (0.05 mg/kg/day) GH therapy in the framework of a 7-day IGF-I generation test. Blood samples were collected on day 1 (D1; pre-dose) and on day 8 (D8; post 7 doses) of GH therapy. All subjects received GH for 12 months at 0.05 mg/kg/day. Serum IGF-I was measured by radioimmunometric assay. Normative historic data from healthy children and those with idiopathic short stature were used for comparison.
Results
Sixteen subjects (age 2–13 years) with creatinine clearances of between 25 and 75 ml/min/1.73 m2 were enrolled. Annualized height velocity for all subjects was 10.3 ±1.1 cm/year (mean ± standard deviation), with an annual change in height Z score of 0.7 ± 1.0. No correlation was found between the generated serum IGF-I levels (D8 − D1) and creatinine clearances, and with changes in height Z scores. Serum IGF-I levels on D1 and D8 in CKD subjects were lower than normative data, but with adequate IGF-I generation on D8.
Conclusions
Children with CKD were able to respond to GH therapy with both growth and an increase in serum IGF-I levels, but the IGF-I generation test was not a good predictor of growth response in this cohort.